|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression |
ISO |
Rifamycins results in increased expression of GSTA1 protein |
CTD |
PMID:7986210 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression |
ISO |
Rifamycins results in decreased expression of GSTM1 protein |
CTD |
PMID:7986210 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
|
G |
Aadac |
arylacetamide deacetylase |
multiple interactions decreases acetylation |
ISO |
AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin] |
CTD |
PMID:21856291 |
|
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Rifabutin results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Rifabutin results in increased expression of ABCB1 mRNA |
CTD |
PMID:37285043 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression affects activity multiple interactions |
ISO |
Rifabutin results in increased expression of CYP3A4 mRNA Rifabutin affects the activity of CYP3A4 protein AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:16837568 PMID:21856291 PMID:37285043 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Rifabutin results in increased activity of NR1I2 protein |
CTD |
PMID:37285043 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Aadac |
arylacetamide deacetylase |
multiple interactions increases hydrolysis decreases acetylation |
ISO |
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin |
CTD |
PMID:21856291 PMID:22207054 |
|
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
ISO |
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein |
CTD |
PMID:15883047 PMID:17088262 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
increases expression |
ISO |
Rifampin results in increased expression of ABCA2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
decreases expression |
ISO |
Rifampin results in decreased expression of ABCA8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression multiple interactions decreases activity |
ISO EXP |
Rifampin results in decreased expression of ABCB11 mRNA [Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein Rifampin results in decreased expression of ABCB11 protein tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein] Rifampin results in decreased activity of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein |
CTD |
PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:25886055 PMID:28437613 PMID:35544702 PMID:35835356 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression decreases activity affects activity |
ISO EXP |
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter] Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate Rifampin affects the activity of ABCB1 protein |
CTD |
PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 PMID:15710169 PMID:15964336 PMID:16819505 PMID:16837569 PMID:16842400 PMID:17003290 PMID:17191263 PMID:17365992 PMID:18094037 PMID:19148864 PMID:19647009 PMID:20018165 PMID:20041327 PMID:20624464 PMID:22258563 PMID:22914566 PMID:23685082 PMID:23707768 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25542144 PMID:26301745 PMID:26394120 PMID:27199754 PMID:27871908 PMID:27918128 PMID:29356861 PMID:30071242 PMID:31233785 PMID:32092453 PMID:33002526 PMID:34689256 PMID:35972551 PMID:36893891 PMID:37285043 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
Rifampin results in increased expression of ABCB4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Rifampin results in increased expression of ABCB6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC1 mRNA |
CTD |
PMID:17191263 PMID:35972551 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export multiple interactions increases expression |
ISO EXP |
ABCC2 protein affects the export of Rifampin [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein |
CTD |
PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 PMID:20832446 PMID:25313206 PMID:27199754 PMID:35835356 More...
|
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression increases activity |
ISO |
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein |
CTD |
PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 PMID:23137910 PMID:27199754 More...
|
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC5 mRNA |
CTD |
PMID:19041851 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcf1 |
ATP binding cassette subfamily F member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCF1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein |
CTD |
PMID:12040753 PMID:17088262 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:16837569 PMID:27199754 PMID:35972551 PMID:38423481 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Abi3 |
ABI family, member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of ABI3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:80,769,819...80,780,816
Ensembl chr10:80,769,822...80,780,816
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Rifampin results in increased expression of ACACA mRNA |
CTD |
PMID:27806127 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein |
CTD |
PMID:36878459 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Actr10 |
actin related protein 10 |
increases expression |
ISO |
Rifampin results in increased expression of ACTR10 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:89,446,141...89,472,350
Ensembl chr 6:89,446,093...89,473,047
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
increases expression |
ISO |
Rifampin results in increased expression of ADH1C mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:33412187 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases expression |
ISO |
Rifampin results in decreased expression of ADORA2A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of AGAP2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:62,897,282...62,914,295
Ensembl chr 7:62,897,282...62,914,295
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein |
CTD |
PMID:22733800 PMID:28428138 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Rifampin results in increased expression of ALAS1 mRNA |
CTD |
PMID:24259679 PMID:24552687 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases activity multiple interactions |
ISO |
Rifampin results in increased activity of ALPL protein [Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein |
CTD |
PMID:25886055 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd65 |
ankyrin repeat domain 65 |
decreases expression |
ISO |
Rifampin results in decreased expression of ANKRD65 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:166,398,359...166,400,616
Ensembl chr 5:166,397,748...166,400,953
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
decreases expression |
ISO |
Rifampin results in decreased expression of ANKS1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apob |
apolipoprotein B |
decreases expression affects secretion multiple interactions |
ISO |
Rifampin results in decreased expression of APOB mRNA Rifampin affects the secretion of APOB protein ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA] |
CTD |
PMID:32535746 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc3 |
apolipoprotein C3 |
decreases expression decreases secretion |
ISO |
Rifampin results in decreased expression of APOC3 mRNA Rifampin results in decreased secretion of APOC3 protein |
CTD |
PMID:32535746 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp4 |
aquaporin 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of AQP4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Arsj |
arylsulfatase family, member J |
decreases expression |
ISO |
Rifampin results in decreased expression of ARSJ mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP ISO |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
Rifampin results in increased expression of ATF6 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions decreases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp6v0a1 |
ATPase H+ transporting V0 subunit a1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of ATP6V0A1 protein [Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein] |
CTD |
PMID:31648047 |
|
NCBI chr10:85,935,802...85,989,901
Ensembl chr10:85,935,854...85,989,895
|
|
G |
Atp6v0d1 |
ATPase H+ transporting V0 subunit D1 |
multiple interactions |
ISO |
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:31648047 |
|
NCBI chr19:33,403,352...33,447,357
Ensembl chr19:33,403,355...33,447,450
|
|
G |
Atrx |
ATRX, chromatin remodeler |
increases expression |
ISO |
Rifampin results in increased expression of ATRX mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 PMID:33629115 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein] |
CTD |
PMID:11958592 PMID:21419764 PMID:31629065 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
C17h9orf153 |
similar to human chromosome 9 open reading frame 153 |
decreases expression |
ISO |
Rifampin results in decreased expression of C9ORF153 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:4,975,415...4,982,400
Ensembl chr17:4,964,834...4,982,766
|
|
G |
C19h4orf51 |
similar to human chromosome 4 open reading frame 51 |
decreases expression |
ISO |
Rifampin results in decreased expression of C4ORF51 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:28,669,044...28,704,512
Ensembl chr19:28,669,059...28,704,508
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein] |
CTD |
PMID:26086368 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3 [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 PMID:26775663 PMID:31678598 PMID:35835356 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein |
CTD |
PMID:36878459 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
EXP |
Rifampin results in decreased expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
Rifampin results in increased expression of CD36 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein |
CTD |
PMID:21224054 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein] |
CTD |
PMID:33412187 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein] |
CTD |
PMID:33412187 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA] |
CTD |
PMID:33412187 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Rifampin results in increased expression of CES1 protein |
CTD |
PMID:10640517 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA] |
CTD |
PMID:10640517 PMID:17003103 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Ciz1 |
CDKN1A interacting zinc finger protein 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CIZ1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:15,658,479...15,673,762
Ensembl chr 3:15,658,539...15,673,762
|
|
G |
Clk2 |
CDC-like kinase 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of CLK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985
|
|
G |
Cntln |
centlein |
increases expression |
ISO |
Rifampin results in increased expression of CNTLN mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:99,295,865...99,576,402
Ensembl chr 5:99,296,000...99,576,396
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Rifampin results in increased expression of CPT1A mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CRHR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein |
CTD |
PMID:16943303 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csnk1g1 |
casein kinase 1, gamma 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CSNK1G1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:66,439,760...66,577,247
Ensembl chr 8:66,439,864...66,572,826
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Rifampin results in increased expression of CXCL1 protein |
CTD |
PMID:25051504 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions affects expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein |
CTD |
PMID:21224054 PMID:25051504 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyb5rl |
cytochrome b5 reductase-like |
increases expression |
ISO |
Rifampin results in increased expression of CYB5RL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:121,846,223...121,868,287
Ensembl chr 5:121,847,952...121,868,745
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression |
EXP ISO |
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 PMID:24999631 PMID:29162470 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO EXP |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein |
CTD |
PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 PMID:30503582 PMID:32633153 More...
|
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21224054 PMID:29162470 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein |
CTD |
PMID:15630458 PMID:21127053 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:17088262 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
increases expression decreases expression |
EXP ISO |
Rifampin results in increased expression of CYP2A1 mRNA Rifampin results in increased expression of CYP2A13 mRNA Rifampin results in decreased expression of CYP2A13 mRNA |
CTD |
PMID:19118567 PMID:22258563 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
Rifampin results in increased expression of CYP2A4 mRNA |
CTD |
PMID:30503582 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases activity multiple interactions increases expression |
ISO |
Rifampin results in increased activity of CYP2B6 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein |
CTD |
PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 PMID:15548381 PMID:15629111 PMID:15802389 PMID:16608920 PMID:17041008 PMID:17438109 PMID:17954527 PMID:18094037 PMID:18332078 PMID:19118567 PMID:19202563 PMID:19497361 PMID:20035023 PMID:20361990 PMID:21224054 PMID:21315811 PMID:22126990 PMID:22258563 PMID:22524704 PMID:22733800 PMID:23732298 PMID:24038852 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25835148 PMID:25929522 PMID:26196221 PMID:27871908 PMID:27917125 PMID:28289823 PMID:28887089 PMID:29356861 PMID:30071242 PMID:30503582 PMID:34689256 More...
|
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein |
CTD |
PMID:22258563 PMID:31629065 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases activity increases expression multiple interactions |
ISO |
Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C29 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein Rifampin results in increased expression of and results in increased activity of CYP2C19 protein |
CTD |
PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 PMID:22126990 PMID:22310298 PMID:24552687 PMID:24830941 PMID:25835148 PMID:27917125 PMID:30503582 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects binding multiple interactions increases expression increases activity |
ISO |
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein |
CTD |
PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 PMID:22126990 PMID:25313206 PMID:29356861 PMID:31629065 More...
|
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases expression increases activity decreases expression |
ISO |
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in increased activity of CYP2D6 protein Rifampin results in decreased expression of CYP2D22 mRNA |
CTD |
PMID:19041851 PMID:30503582 PMID:33844597 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity decreases expression multiple interactions increases expression |
ISO EXP |
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein] |
CTD |
PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 PMID:27919644 PMID:30503582 PMID:32633153 More...
|
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22258563 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2J2 mRNA |
CTD |
PMID:33263786 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions affects activity increases expression decreases response to substance increases activity |
EXP ISO |
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CYP3A4 protein results in decreased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 PMID:10859152 PMID:11581012 PMID:12040753 PMID:12065438 PMID:12072427 PMID:12235278 PMID:12417264 PMID:12505310 PMID:12584154 PMID:12642470 PMID:12673034 PMID:12695340 PMID:12695342 PMID:12851153 PMID:14600250 PMID:14636322 PMID:14709624 PMID:14722322 PMID:14977870 PMID:15075359 PMID:15466163 PMID:15548381 PMID:15554232 PMID:15629111 PMID:15681896 PMID:15710169 PMID:15769886 PMID:15771232 PMID:15802389 PMID:15833926 PMID:15855724 PMID:15964336 PMID:15977188 PMID:16146350 PMID:16184197 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16837568 PMID:17003103 PMID:17041008 PMID:17270371 PMID:17293382 PMID:17438109 PMID:17590308 PMID:17936189 PMID:17954527 PMID:17998298 PMID:18094037 PMID:18332045 PMID:18332078 PMID:18505790 PMID:18799805 PMID:18839173 PMID:19041297 PMID:19118567 PMID:19135037 PMID:19202563 PMID:19230594 PMID:19686824 PMID:19854261 PMID:20035023 PMID:20035846 PMID:20233841 PMID:20361990 PMID:20599501 PMID:21127053 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21856291 PMID:21920351 PMID:21924250 PMID:21998292 PMID:22093699 PMID:22126990 PMID:22159698 PMID:22178124 PMID:22258563 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22524704 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22843569 PMID:22982774 PMID:23153560 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24038852 PMID:24146111 PMID:24204015 PMID:24259679 PMID:24552687 PMID:24685772 PMID:24752503 PMID:24999631 PMID:25069801 PMID:25084468 PMID:25313206 PMID:25455453 PMID:25512232 PMID:25542144 PMID:25616597 PMID:25929522 PMID:26196221 PMID:26201057 PMID:26301745 PMID:26341324 PMID:26616219 PMID:27177772 PMID:27180241 PMID:27507784 PMID:27590069 PMID:27794450 PMID:27871908 PMID:27917125 PMID:27919644 PMID:28289823 PMID:28571685 PMID:28887089 PMID:28916285 PMID:29162470 PMID:29356861 PMID:29933105 PMID:30044681 PMID:30071242 PMID:30087611 PMID:31132328 PMID:31233785 PMID:31870919 PMID:31877331 PMID:32092453 PMID:32682830 PMID:33002526 PMID:33263786 PMID:33629115 PMID:33844597 PMID:34021354 PMID:34689256 PMID:36288780 PMID:36893891 PMID:37285043 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] |
CTD |
PMID:12370413 PMID:19041297 PMID:22159698 PMID:22310326 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
Rifampin results in increased expression of CYP3A5 mRNA |
CTD |
PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 PMID:20832446 PMID:24146111 PMID:24259679 PMID:28496040 More...
|
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein Rifampin results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 PMID:34689256 PMID:35835356 More...
|
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dcaf5 |
DDB1 and CUL4 associated factor 5 |
decreases expression |
ISO |
Rifampin results in decreased expression of DCAF5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110
|
|
G |
Dclre1b |
DNA cross-link repair 1B |
decreases expression |
ISO |
Rifampin results in decreased expression of DCLRE1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein |
CTD |
PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
multiple interactions |
ISO |
[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA |
CTD |
PMID:22101211 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
increases expression |
ISO |
Rifampin results in increased expression of DIO1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dlx4 |
distal-less homeobox 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of DLX4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:80,085,037...80,090,434
Ensembl chr10:80,085,465...80,090,456
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA |
CTD |
PMID:21127053 PMID:21224054 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Egr4 |
early growth response 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation increases expression multiple interactions |
EXP ISO |
Rifampin results in increased phosphorylation of EIF2AK3 protein Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
Rifampin results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:24638036 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
decreases expression |
ISO |
Rifampin results in decreased expression of ELK1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of EPHX1 mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA] |
CTD |
PMID:22258563 PMID:25313206 PMID:29356861 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
ISO |
Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein Rifampin results in increased expression of ERN1 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
increases expression |
ISO |
Rifampin results in increased expression of ETNPPL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212
|
|
G |
F13b |
coagulation factor XIII B chain |
increases expression |
ISO |
Rifampin results in increased expression of F13B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr13:51,130,908...51,156,383
Ensembl chr13:51,130,920...51,156,381
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions decreases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression affects expression multiple interactions |
ISO |
Rifampin results in increased expression of FASN mRNA Rifampin affects the expression of FASN mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA] |
CTD |
PMID:27806127 PMID:29356861 PMID:34689256 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions increases expression |
ISO |
[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA Rifampin results in increased expression of FGF19 mRNA |
CTD |
PMID:17696253 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fmo4 |
flavin containing dimethylaniline monoxygenase 4 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Foxp1 |
forkhead box P1 |
increases expression |
ISO |
Rifampin results in increased expression of FOXP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Fut1 |
fucosyltransferase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of FUT1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions decreases expression affects expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin results in decreased expression of G6PC1 mRNA |
CTD |
PMID:24204015 PMID:34689256 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA] |
CTD |
PMID:21127053 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gata5 |
GATA binding protein 5 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751
|
|
G |
Gck |
glucokinase |
decreases expression multiple interactions |
ISO |
Rifampin results in decreased expression of GCK protein NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein] |
CTD |
PMID:26616219 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Glis2 |
GLIS family zinc finger 2 |
increases expression |
ISO |
Rifampin results in increased expression of GLIS2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578
|
|
G |
Gnal |
G protein subunit alpha L |
decreases expression |
ISO |
Rifampin results in decreased expression of GNAL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions increases activity |
ISO |
[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein Rifampin results in increased activity of GOT1 protein |
CTD |
PMID:25886055 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity increases expression |
ISO EXP |
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein Rifampin results in increased activity of GPT protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein] [Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein] |
CTD |
PMID:24685772 PMID:25886055 PMID:27470132 PMID:31678598 PMID:32633153 PMID:35544702 PMID:35835356 PMID:36878459 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA |
CTD |
PMID:21224054 PMID:33629115 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein] |
CTD |
PMID:36878459 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of GRIA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases activity |
ISO |
Rifampin results in increased activity of GSR protein |
CTD |
PMID:20848779 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA] |
CTD |
PMID:16608920 PMID:19118567 PMID:29162470 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein |
CTD |
PMID:21224054 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide] |
CTD |
PMID:18397238 PMID:20485159 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2ird2 |
GTF2I repeat domain containing 2 |
increases expression |
ISO |
Rifampin results in increased expression of GTF2IRD2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:22,497,767...22,536,455
Ensembl chr12:22,498,091...22,536,263
|
|
G |
Gzmb |
granzyme B |
increases secretion |
ISO |
Rifampin results in increased secretion of GZMB protein |
CTD |
PMID:27933861 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA |
CTD |
PMID:21127053 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hdac3 |
histone deacetylase 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:23764483 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein] |
CTD |
PMID:21127053 PMID:36878459 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgn5 |
high mobility group nucleosome binding domain 5 |
increases expression |
ISO |
Rifampin results in increased expression of HMGN5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441 Ensembl chr 1:74,085,875...74,094,441
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein] Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein [arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA |
CTD |
PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
ISO |
[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein] |
CTD |
PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hrh1 |
histamine receptor H 1 |
increases expression |
ISO |
Rifampin results in increased expression of HRH1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA |
CTD |
PMID:21224054 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP ISO |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein |
CTD |
PMID:24638036 PMID:27470132 PMID:32535746 PMID:33629115 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Ifng |
interferon gamma |
increases secretion |
ISO |
Rifampin results in increased secretion of IFNG protein |
CTD |
PMID:27933861 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il10 |
interleukin 10 |
affects expression |
EXP |
Rifampin affects the expression of IL10 protein |
CTD |
PMID:25051504 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of IL12RB2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289
|
|
G |
Il13 |
interleukin 13 |
increases secretion |
ISO |
Rifampin results in increased secretion of IL13 protein |
CTD |
PMID:27933861 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein |
CTD |
PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions increases expression |
ISO EXP |
Rifampin results in decreased expression of IL6 protein Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA] Rifampin results in increased expression of IL6 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA |
CTD |
PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ino80d |
INO80 complex subunit D |
decreases expression |
ISO |
Rifampin results in decreased expression of INO80D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:64,447,075...64,514,013
Ensembl chr 9:64,457,165...64,515,242
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein] |
CTD |
PMID:24204015 PMID:33412187 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Ints6 |
integrator complex subunit 6 |
decreases expression |
ISO |
Rifampin results in decreased expression of INTS6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527
|
|
G |
Iqca1 |
IQ motif containing with AAA domain 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of IQCA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:90,626,744...90,742,618
|
|
G |
Itgbl1 |
integrin subunit beta like 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kirrel3 |
kirre like nephrin family adhesion molecule 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of KIRREL3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:32,865,779...33,407,555
Ensembl chr 8:32,862,776...33,405,676
|
|
G |
Klf2 |
KLF transcription factor 2 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf5 |
KLF transcription factor 5 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Rifampin results in increased expression of LDLR mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lefty1 |
left right determination factor 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720
|
|
G |
Lep |
leptin |
increases expression |
EXP |
Rifampin results in increased expression of LEP protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Ltk |
leukocyte receptor tyrosine kinase |
increases expression |
ISO |
Rifampin results in increased expression of LTK mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:106,734,675...106,741,552
Ensembl chr 3:106,734,676...106,743,369
|
|
G |
Maff |
MAF bZIP transcription factor F |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases metabolic processing multiple interactions increases lipidation |
ISO |
Rifampin results in decreased metabolism of MAP1LC3B protein ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:29908302 PMID:31648047 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:31648047 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
increases phosphorylation |
ISO |
Rifampin results in increased phosphorylation of MAPKAPK2 protein |
CTD |
PMID:21127053 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mapre3 |
microtubule-associated protein, RP/EB family, member 3 |
increases expression |
ISO |
Rifampin results in increased expression of MAPRE3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881
|
|
G |
Matn2 |
matrilin 2 |
increases expression |
ISO |
Rifampin results in increased expression of MATN2 mRNA |
CTD |
PMID:27177772 |
|
NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113
|
|
G |
Mbp |
myelin basic protein |
affects expression |
EXP |
Rifampin affects the expression of MBP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein |
CTD |
PMID:31629065 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions decreases expression |
ISO |
Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein] Rifampin results in decreased expression of MED1 mRNA |
CTD |
PMID:21292004 PMID:22214767 PMID:24552687 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Minpp1 |
multiple inositol-polyphosphate phosphatase 1 |
increases expression |
ISO |
Rifampin results in increased expression of MINPP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:230,354,483...230,379,730
Ensembl chr 1:230,354,438...230,379,730
|
|
G |
Mir143 |
microRNA 143 |
increases expression |
ISO |
Rifampin results in increased expression of MIR143 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110
|
|
G |
Mir145 |
microRNA 145 |
increases expression |
ISO |
Rifampin results in increased expression of MIR145 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir148b |
microRNA 148b |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR148B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494
|
|
G |
Mir15b |
microRNA 15b |
increases expression |
ISO |
Rifampin results in increased expression of MIR15B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297
|
|
G |
Mir186 |
microRNA 186 |
multiple interactions |
ISO |
[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA |
CTD |
PMID:32633153 |
|
NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891
|
|
G |
Mir192 |
microRNA 192 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR192 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055
|
|
G |
Mir200a |
microRNA 200a |
increases expression |
ISO |
Rifampin results in increased expression of MIR200A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:166,648,494...166,648,582
|
|
G |
Mir202 |
microRNA 202 |
increases expression |
ISO |
Rifampin results in increased expression of MIR202 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:194,754,730...194,754,801
Ensembl chr 1:194,754,730...194,754,801
|
|
G |
Mir204 |
microRNA 204 |
increases expression |
ISO |
Rifampin results in increased expression of MIR204 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:220,316,931...220,317,040
Ensembl chr 1:220,316,931...220,317,040
|
|
G |
Mir20b |
microRNA 20b |
increases expression |
ISO |
Rifampin results in increased expression of MIR20B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282
|
|
G |
Mir21 |
microRNA 21 |
increases expression |
ISO |
Rifampin results in increased expression of MIR21 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir212 |
microRNA 212 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR212 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:60,023,403...60,023,513
Ensembl chr10:60,023,403...60,023,513
|
|
G |
Mir22 |
microRNA 22 |
increases expression |
ISO |
Rifampin results in increased expression of MIR22 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133
|
|
G |
Mir26b |
microRNA 26b |
increases expression |
ISO |
Rifampin results in increased expression of MIR26B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:75,976,596...75,976,680
Ensembl chr 9:75,976,596...75,976,680
|
|
G |
Mir296 |
microRNA 296 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR296 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:163,051,838...163,051,915
Ensembl chr 3:163,051,838...163,051,915
|
|
G |
Mir29a |
microRNA 29a |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR29A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:59,650,608...59,650,695
|
|
G |
Mir31 |
microRNA 31 |
increases expression |
ISO |
Rifampin results in increased expression of MIR31 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:103,599,038...103,599,143
|
|
G |
Mir328 |
microRNA 328 |
increases expression |
ISO |
Rifampin results in increased expression of MIR328 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849
|
|
G |
Mir340-1 |
microRNA 340-1 |
increases expression |
ISO |
Rifampin results in increased expression of MIR340 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:34,393,568...34,393,665
Ensembl chr10:34,393,568...34,393,665
|
|
G |
Mir34a |
microRNA 34a |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR34A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mir374b |
microRNA 374b |
increases expression |
ISO |
Rifampin results in increased expression of MIR374B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:68,591,732...68,591,799
Ensembl chr X:68,591,732...68,591,799
|
|
G |
Mir532 |
microRNA 532 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR532 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393
|
|
G |
Mir628 |
microRNA 628 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR628 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:73,739,846...73,739,929
Ensembl chr 8:73,739,846...73,739,929
|
|
G |
Mir652 |
microRNA 652 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR652 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:106,343,293...106,343,373
Ensembl chr X:106,343,293...106,343,373
|
|
G |
Mir874 |
microRNA 874 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR874 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:6,620,649...6,620,724
Ensembl chr17:6,620,649...6,620,724
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein |
CTD |
PMID:21224054 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
decreases secretion |
ISO |
Rifampin results in decreased secretion of MMP3 protein |
CTD |
PMID:24890593 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:24101390 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
affects expression |
ISO |
Rifampin affects the expression of MR1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression |
ISO |
Rifampin results in decreased expression of MTTP mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myh6 |
myosin heavy chain 6 |
increases expression |
ISO |
Rifampin results in increased expression of MYH6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Naf1 |
nuclear assembly factor 1 ribonucleoprotein |
decreases expression |
ISO |
Rifampin results in decreased expression of NAF1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293
|
|
G |
Nap1l5 |
nucleosome assembly protein 1-like 5 |
increases expression |
ISO |
Rifampin results in increased expression of NAP1L5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein] |
CTD |
PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 PMID:17998298 PMID:21115105 PMID:21292004 PMID:22214767 PMID:23525103 PMID:25313206 PMID:26920453 PMID:27871908 PMID:28289823 PMID:29356861 More...
|
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein] |
CTD |
PMID:21292004 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncoa6 |
nuclear receptor coactivator 6 |
multiple interactions |
ISO |
NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein] |
CTD |
PMID:21292004 |
|
NCBI chr 3:143,890,896...143,961,916
Ensembl chr 3:143,890,896...143,952,268
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein] |
CTD |
PMID:22214767 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein] |
CTD |
PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 PMID:29356861 More...
|
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions decreases expression decreases activity |
ISO EXP |
Rifampin results in increased expression of NFE2L2 protein [tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein] Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein] Rifampin results in decreased activity of NFE2L2 protein |
CTD |
PMID:31678598 PMID:33307820 PMID:33412187 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfya |
nuclear transcription factor Y subunit alpha |
decreases expression |
ISO |
Rifampin results in decreased expression of NFYA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:12,587,437...12,613,911
Ensembl chr 9:12,586,259...12,613,898
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of TNFRSF10B mRNA |
CTD |
PMID:33629115 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein] |
CTD |
PMID:26086368 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA Rifampin results in increased expression of NOS2 mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas1 |
neuronal PAS domain protein 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:77,167,375...77,187,887
Ensembl chr 1:77,167,381...77,186,762
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression decreases expression |
ISO |
Rifampin results in increased expression of NR0B2 mRNA Rifampin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:15670600 PMID:34689256 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:23732298 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP ISO |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4 |
CTD |
PMID:35835356 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance affects localization decreases acetylation increases response to substance increases activity decreases response to substance multiple interactions increases expression increases localization affects binding |
ISO EXP |
NR1I2 protein affects the susceptibility to Rifampin Rifampin affects the localization of NR1I2 protein Rifampin results in decreased acetylation of NR1I2 protein NR1I2 protein results in increased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein NR1I2 protein mutant form results in decreased susceptibility to Rifampin 1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; triptolide inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein Rifampin results in increased localization of NR1I2 protein [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] Rifampin binds to NR1I2 gene mutant form [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein |
CTD |
PMID:11581012 PMID:12065438 PMID:12072427 PMID:12370413 PMID:12417264 PMID:12695340 PMID:12695351 PMID:14570758 PMID:14600250 PMID:14636322 PMID:14977870 PMID:15489543 PMID:15548381 PMID:15630458 PMID:15670600 PMID:15705662 PMID:15802384 PMID:15833926 PMID:15849716 PMID:15864135 PMID:15883047 PMID:15885729 PMID:15933212 PMID:16267138 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16857725 PMID:17003103 PMID:17041008 PMID:17088262 PMID:17438109 PMID:17696253 PMID:17936928 PMID:17998298 PMID:18098064 PMID:18180267 PMID:18692084 PMID:18799805 PMID:19249324 PMID:19647009 PMID:19889628 PMID:20041327 PMID:20079722 PMID:20143881 PMID:20361990 PMID:20624464 PMID:20869355 PMID:21115097 PMID:21115105 PMID:21127053 PMID:21227907 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21924250 PMID:22093699 PMID:22101211 PMID:22159698 PMID:22206814 PMID:22214767 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22467028 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22982774 PMID:23439660 PMID:23525103 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24204015 PMID:25069801 PMID:25313206 PMID:25455453 PMID:25472953 PMID:25542144 PMID:25616597 PMID:25680588 PMID:25835148 PMID:26187274 PMID:26196221 PMID:26238175 PMID:26341324 PMID:26616219 PMID:26778350 PMID:26883953 PMID:26920453 PMID:27177772 PMID:27180241 PMID:27806127 PMID:27871908 PMID:27918128 PMID:28115241 PMID:28259787 PMID:28289823 PMID:28428138 PMID:28496040 PMID:28887089 PMID:29356861 PMID:29933105 PMID:30071242 PMID:30394306 PMID:30582956 PMID:31233785 PMID:31472229 PMID:32092453 PMID:33002526 PMID:33629115 PMID:35678845 PMID:36893891 PMID:37285043 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression multiple interactions |
EXP ISO |
Rifampin results in increased expression of NR1I3 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein |
CTD |
PMID:19118567 PMID:22733800 PMID:25835148 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases expression |
ISO |
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Rifampin results in increased expression of NR3C1 mRNA |
CTD |
PMID:10219967 PMID:12673034 PMID:12695351 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrl |
neural retina leucine zipper |
increases expression |
ISO |
Rifampin results in increased expression of NRL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:29,007,059...29,011,480
Ensembl chr15:29,008,104...29,009,832
|
|
G |
Obsl1 |
obscurin like cytoskeletal adaptor 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of OBSL1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:76,967,802...76,993,771
Ensembl chr 9:76,974,253...76,993,560
|
|
G |
Ocln |
occludin |
affects localization |
ISO |
Rifampin affects the localization of OCLN protein |
CTD |
PMID:19577586 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Or4a47 |
olfactory receptor family 4 subfamily A member 47 |
decreases expression |
ISO |
Rifampin results in decreased expression of OR4A47 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:75,873,971...75,874,900
Ensembl chr 3:75,871,362...75,879,648
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
decreases expression |
ISO |
Rifampin results in decreased expression of P4HB mRNA |
CTD |
PMID:32535746 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein] |
CTD |
PMID:31678598 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax7 |
paired box 7 |
decreases expression |
ISO |
Rifampin results in decreased expression of PAX7 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:151,996,368...152,098,023
Ensembl chr 5:151,999,092...152,097,979
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of PCK1 mRNA |
CTD |
PMID:24204015 PMID:34689256 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pclaf |
PCNA clamp associated factor |
increases expression |
ISO |
Rifampin results in increased expression of PCLAF mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pdap1 |
PDGFA associated protein 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of PDAP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374
|
|
G |
Pde4d |
phosphodiesterase 4D |
decreases expression |
ISO |
Rifampin results in decreased expression of PDE4D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884
|
|
G |
Peg3 |
paternally expressed 3 |
increases expression |
ISO |
Rifampin results in increased expression of PEG3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:67,097,874...67,124,692
Ensembl chr 1:67,097,904...67,124,671
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
|
|
G |
Pilra |
paired immunoglobin-like type 2 receptor alpha |
decreases expression |
ISO |
Rifampin results in decreased expression of PILRA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:17,787,169...17,798,149
Ensembl chr12:17,787,127...17,798,094
|
|
G |
Pip4k2a |
phosphatidylinositol-5-phosphate 4-kinase type 2 alpha |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:81,496,669...81,668,180
Ensembl chr17:81,496,670...81,668,029
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
decreases expression |
ISO |
Rifampin results in decreased expression of PKD2L1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:243,032,891...243,070,031
Ensembl chr 1:243,032,913...243,070,031
|
|
G |
Pklr |
pyruvate kinase L/R |
increases expression |
ISO |
Rifampin results in increased expression of PKLR mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Plat |
plasminogen activator, tissue type |
decreases expression |
ISO |
Rifampin results in decreased expression of PLAT mRNA |
CTD |
PMID:24552687 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
Rifampin results in increased expression of PON1 mRNA |
CTD |
PMID:26434531 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases activity |
ISO |
Rifampin results in increased activity of POR protein |
CTD |
PMID:12051692 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pou2f1 |
POU class 2 homeobox 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of POU2F1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr13:78,120,617...78,263,306
Ensembl chr13:78,130,685...78,263,363
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA [Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein |
CTD |
PMID:16292757 PMID:36347327 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein Rifampin results in increased expression of PPARG mRNA |
CTD |
PMID:27806127 PMID:33412187 PMID:36347327 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein] |
CTD |
PMID:16857725 PMID:21292004 PMID:25069801 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline] |
CTD |
PMID:21224054 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
multiple interactions |
ISO |
PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:31877331 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prune1 |
prune exopolyphosphatase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of PRUNE1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:182,830,575...182,859,972
Ensembl chr 2:182,830,578...182,859,336
|
|
G |
Psip1 |
PC4 and SRSF1 interacting protein 1 |
increases expression |
ISO |
Rifampin results in increased expression of PSIP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257
|
|
G |
Psmc3ip |
PSMC3 interacting protein |
increases expression |
ISO |
Rifampin results in increased expression of PSMC3IP mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:86,024,281...86,027,928
Ensembl chr10:86,023,950...86,027,423
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Ric8b |
RIC8 guanine nucleotide exchange factor B |
decreases expression |
ISO |
Rifampin results in decreased expression of RIC8B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:18,746,716...18,843,264
Ensembl chr 7:18,748,641...18,842,372
|
|
G |
Rnf6 |
ring finger protein 6 |
decreases expression |
ISO |
Rifampin results in decreased expression of RNF6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:8,816,797...8,826,870
Ensembl chr12:8,816,833...8,826,847
|
|
G |
RragB |
Ras-related GTP binding B |
decreases expression |
ISO |
Rifampin results in decreased expression of RRAGB mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:18,184,619...18,234,639
Ensembl chr X:18,184,992...18,234,639
|
|
G |
Rspo3 |
R-spondin 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of RSPO3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:28,283,914...28,368,661
Ensembl chr 1:28,283,914...28,367,061
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Rifampin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-DMa |
RT1 class II, locus DMa |
increases expression |
ISO |
Rifampin results in increased expression of HLA-DMA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
Rifampin affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO EXP |
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] |
CTD |
PMID:12370413 PMID:16292757 PMID:16632523 PMID:21315811 PMID:25069801 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SCARB1 mRNA; Rifampin results in decreased expression of SCARB1 protein |
CTD |
PMID:15883047 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Rifampin results in increased expression of SCD1 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Septin8 |
septin 8 |
increases expression |
ISO |
Rifampin results in increased expression of SEPTIN8 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:37,684,649...37,713,704
Ensembl chr10:37,684,639...37,713,174
|
|
G |
Serpina4 |
serpin family A member 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:122,999,970...123,009,083
Ensembl chr 6:122,999,900...123,009,082
|
|
G |
Serpinb1a |
serpin family B member 1A |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
|
|
G |
Serpinb8 |
serpin family B member 8 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr13:23,626,936...23,650,277
Ensembl chr13:23,626,945...23,650,835
|
|
G |
Serpinb9 |
serpin family B member 9 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA Rifampin results in increased expression of SERPINB9 mRNA |
CTD |
PMID:21127053 PMID:24552687 |
|
NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:21127053 PMID:21224054 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sfxn1 |
sideroflexin 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SFXN1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:10,486,250...10,522,640
Ensembl chr17:10,486,271...10,522,529
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of SGK2 mRNA |
CTD |
PMID:21127053 PMID:24204015 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Sik2 |
salt-inducible kinase 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SIK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:51,225,543...51,325,343
Ensembl chr 8:51,225,543...51,325,415
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression multiple interactions |
ISO EXP |
Rifampin results in decreased expression of SLC10A1 mRNA Rifampin results in decreased expression of SLC10A1 protein [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 mRNA; [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 protein; tanshinone inhibits the reaction [Rifampin results in decreased expression of SLC10A1 protein] [Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1 |
CTD |
PMID:16837569 PMID:25886055 PMID:33307820 PMID:35835356 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc13a5 |
solute carrier family 13 member 5 |
increases expression |
ISO |
Rifampin results in increased expression of SLC13A5 mRNA; Rifampin results in increased expression of SLC13A5 protein |
CTD |
PMID:25628225 PMID:27199754 |
|
NCBI chr10:56,866,249...56,891,189
Ensembl chr10:56,866,249...56,890,945
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC15A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc16a12 |
solute carrier family 16, member 12 |
increases expression decreases expression |
ISO |
Rifampin results in increased expression of SLC16A12 mRNA Rifampin results in decreased expression of SLC16A12 mRNA |
CTD |
PMID:24552687 PMID:27199754 |
|
NCBI chr 1:232,184,004...232,262,170
Ensembl chr 1:232,185,907...232,262,141
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc20a2 |
solute carrier family 20 member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC20A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr16:69,460,850...69,551,418
Ensembl chr16:69,460,462...69,521,711
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases expression multiple interactions |
ISO |
Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA] |
CTD |
PMID:26920453 PMID:27199754 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC22A9 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:16837569 PMID:27199754 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
ISO |
Rifampin results in increased expression of SLC23A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc23a3 |
solute carrier family 23, member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC23A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:76,622,621...76,633,188
Ensembl chr 9:76,622,800...76,631,366
|
|
G |
Slc25a22 |
solute carrier family 25 member 22 |
increases expression |
ISO |
Rifampin results in increased expression of SLC25A22 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:196,528,471...196,536,398
Ensembl chr 1:196,528,472...196,536,331
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC25A34 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 5:153,932,081...153,936,854
|
|
G |
Slc25a40 |
solute carrier family 25, member 40 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC25A40 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:25,631,447...25,676,454
Ensembl chr 4:25,589,360...25,676,472
|
|
G |
Slc26a2 |
solute carrier family 26 member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC26A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr18:54,648,276...54,666,627
Ensembl chr18:54,652,951...54,666,626
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC26A4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A1 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc27a3 |
solute carrier family 27 member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC27A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A5 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC29A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
increases expression |
ISO |
Rifampin results in increased expression of SLC29A4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
increases expression |
ISO |
Rifampin results in increased expression of SLC2A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:22,804,418...22,860,971
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions decreases expression |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein] Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein |
CTD |
PMID:26616219 PMID:27199754 PMID:34689256 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc30a10 |
solute carrier family 30, member 10 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC30A10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC3A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Slc46a3 |
solute carrier family 46, member 3 |
increases expression |
ISO |
Rifampin results in increased expression of SLC46A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr12:7,140,610...7,157,093
Ensembl chr12:7,140,668...7,157,092
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC47A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc51a |
solute carrier family 51 member A |
increases expression |
ISO |
Rifampin results in increased expression of SLC51A mRNA |
CTD |
PMID:27199754 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
SLC51 subunit beta |
increases expression |
ISO |
Rifampin results in increased expression of SLC51B mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc5a11 |
solute carrier family 5 member 11 |
increases expression |
ISO |
Rifampin results in increased expression of SLC5A11 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:177,735,511...177,795,193
Ensembl chr 1:177,756,561...177,795,193
|
|
G |
Slc5a12 |
solute carrier family 5 member 12 |
increases expression |
ISO |
Rifampin results in increased expression of SLC5A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:97,179,326...97,228,405
Ensembl chr 3:97,179,326...97,228,405
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
increases expression |
ISO |
Rifampin results in increased expression of SLC6A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 4:154,585,386...154,603,750
Ensembl chr 4:154,585,500...154,603,750
|
|
G |
Slc6a20a |
solute carrier family 6 member 20a |
increases expression |
ISO |
Rifampin results in increased expression of SLC6A20 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 8:123,282,325...123,322,609
Ensembl chr 8:123,281,472...123,322,573
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
ISO |
Rifampin results in increased expression of SLC6A9 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein] |
CTD |
PMID:36878459 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slc9a8 |
solute carrier family 9 member A8 |
increases expression |
ISO |
Rifampin results in increased expression of SLC9A8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:156,147,855...156,198,497
Ensembl chr 3:156,148,104...156,198,471
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions decreases activity |
EXP ISO |
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1A4 protein |
CTD |
PMID:11883641 PMID:34619012 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions decreases activity decreases expression |
ISO |
Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1B3 protein Rifampin results in decreased expression of SLCO1B3 mRNA |
CTD |
PMID:17369605 PMID:18180276 PMID:21256917 PMID:21430235 PMID:27199754 PMID:31299240 PMID:31830554 PMID:32003934 PMID:32305507 PMID:34619012 More...
|
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco1c1 |
solute carrier organic anion transporter family, member 1c1 |
decreases activity multiple interactions |
EXP |
Rifampin results in decreased activity of SLCO1B1 protein [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate |
CTD |
PMID:32259555 |
|
NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [decitabine results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:23137910 |
|
NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression decreases expression multiple interactions |
ISO |
Rifampin results in increased expression of SLCO2B1 mRNA Rifampin results in decreased expression of SLCO2B1 mRNA; Rifampin results in decreased expression of SLCO2B1 protein Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [Lipopolysaccharides results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 PMID:27199754 PMID:38423481 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases expression |
ISO |
Rifampin results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715
|
|
G |
Smad9 |
SMAD family member 9 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases sumoylation |
EXP |
Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein] |
CTD |
PMID:17280646 PMID:28132806 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Snora71c |
small nucleolar RNA, H/ACA box 71C |
decreases expression |
ISO |
Rifampin results in decreased expression of SNORA71C mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:147,017,736...147,017,867
Ensembl chr 3:147,017,736...147,017,867
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sorbs1 |
sorbin and SH3 domain containing 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SORBS1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169
|
|
G |
Sptb |
spectrin, beta, erythrocytic |
increases expression |
ISO |
Rifampin results in increased expression of SPTB mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:95,310,342...95,437,221
Ensembl chr 6:95,310,326...95,437,118
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Rifampin results in increased expression of SQSTM1 protein |
CTD |
PMID:29908302 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:25069801 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stk39 |
serine threonine kinase 39 |
increases expression |
ISO |
Rifampin results in increased expression of STK39 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:52,913,583...53,179,060
Ensembl chr 3:52,913,585...53,179,060
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer] |
CTD |
PMID:21764778 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO EXP |
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] |
CTD |
PMID:12370413 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
increases expression |
EXP |
Rifampin results in increased expression of SUMO1 protein |
CTD |
PMID:28132806 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Sumo3 |
small ubiquitin-like modifier 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr20:11,010,140...11,020,850
Ensembl chr20:11,007,148...11,020,877 Ensembl chr20:11,007,148...11,020,877
|
|
G |
Sun1 |
Sad1 and UNC84 domain containing 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SUN1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:15,396,378...15,441,277
Ensembl chr12:15,396,381...15,441,571
|
|
G |
Tbata |
thymus, brain and testes associated |
decreases expression |
ISO |
Rifampin results in decreased expression of TBATA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:29,118,055...29,135,124
Ensembl chr20:29,118,070...29,135,109
|
|
G |
Tfec |
transcription factor EC |
increases expression |
ISO |
Rifampin results in increased expression of TFEC mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:45,106,129...45,180,236
Ensembl chr 4:45,107,641...45,180,236
|
|
G |
Thsd4 |
thrombospondin type 1 domain containing 4 |
increases expression |
ISO |
Rifampin results in increased expression of THSD4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:60,386,875...61,024,995
|
|
G |
Tjp1 |
tight junction protein 1 |
affects localization decreases expression |
ISO |
Rifampin affects the localization of TJP1 protein Rifampin results in decreased expression of TJP1 mRNA |
CTD |
PMID:19577586 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tjp2 |
tight junction protein 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of TJP2 mRNA |
CTD |
PMID:19577586 |
|
NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Rifampin results in increased expression of TLR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125
|
|
G |
Tmem120b |
transmembrane protein 120B |
decreases expression |
ISO |
Rifampin results in decreased expression of TMEM120B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:33,447,441...33,487,257
Ensembl chr12:33,446,660...33,487,200
|
|
G |
Tmem145 |
transmembrane protein 145 |
increases expression |
ISO |
Rifampin results in increased expression of TMEM145 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:80,891,888...80,901,615
Ensembl chr 1:80,891,927...80,901,611
|
|
G |
Tmem88 |
transmembrane protein 88 |
increases expression |
ISO |
Rifampin results in increased expression of TMEM88 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:54,118,752...54,120,447
Ensembl chr10:54,118,752...54,120,447
|
|
G |
Tmprss2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Rifampin results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr11:36,934,306...36,973,779
Ensembl chr11:36,934,306...36,973,715
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
Rifampin results in decreased expression of TNF protein |
CTD |
PMID:21357946 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA |
CTD |
PMID:21224054 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Tsku |
tsukushi, small leucine rich proteoglycan |
increases expression |
ISO |
Rifampin results in increased expression of TSKU mRNA |
CTD |
PMID:24552687 PMID:27177772 |
|
NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
multiple interactions |
EXP |
UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein] |
CTD |
PMID:28132806 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA Rifampin results in increased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression increases expression multiple interactions |
ISO |
Rifampin affects the expression of UGT1A1 mRNA Rifampin results in increased expression of UGT1A1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA |
CTD |
PMID:15104253 PMID:15771232 PMID:15849716 PMID:18098064 PMID:22126990 PMID:24259679 PMID:29162470 PMID:31233785 PMID:36893891 More...
|
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of UGT1A3 mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of UGT1A3 mRNA] |
CTD |
PMID:25313206 PMID:29356861 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression |
ISO |
Rifampin results in increased expression of UGT1A6 mRNA |
CTD |
PMID:18094037 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases expression |
ISO |
Rifampin results in increased expression of UGT1A9 mRNA; Rifampin results in increased expression of UGT1A9 protein |
CTD |
PMID:25070100 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Uhrf2 |
ubiquitin like with PHD and ring finger domains 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of UHRF2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:227,814,639...227,877,907
Ensembl chr 1:227,814,963...227,877,904
|
|
G |
Ung |
uracil-DNA glycosylase |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206
|
|
G |
Usp17la2 |
ubiquitin specific peptidase 17-like a2 |
decreases expression |
ISO |
Rifampin results in decreased expression of USP17L2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:159,151,417...159,155,192
Ensembl chr 1:159,151,432...159,155,192
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
EXP |
Rifampin results in increased expression of VEGFA protein |
CTD |
PMID:25051504 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfd |
vascular endothelial growth factor D |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA |
CTD |
PMID:21127053 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vkorc1 |
vitamin K epoxide reductase complex, subunit 1 |
affects response to substance |
ISO |
VKORC1 alternative form affects the susceptibility to Rifampin |
CTD |
PMID:36789833 |
|
NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008
|
|
G |
Vwa1 |
von Willebrand factor A domain containing 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of VWA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:166,377,451...166,382,784
Ensembl chr 5:166,377,455...166,382,637
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
Rifampin results in increased expression of XIAP protein |
CTD |
PMID:12645856 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
G |
Zcchc13 |
zinc finger CCHC-type containing 13 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZCCHC13 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:68,643,568...68,644,671
Ensembl chr X:68,643,549...68,665,131
|
|
G |
Zfp11 |
zinc finger protein 11 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF546 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:27,028,067...27,040,846
Ensembl chr12:27,028,115...27,041,365
|
|
G |
Zfp451 |
zinc finger protein 451 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF451 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:35,985,441...36,040,991
Ensembl chr 9:35,985,443...36,040,652
|
|
G |
Zfp46 |
zinc finger protein 46 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF436 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:148,519,398...148,529,903
Ensembl chr 5:148,520,855...148,529,459
|
|
G |
Zfp462 |
zinc finger protein 462 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF462 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:69,670,085...69,810,729
Ensembl chr 5:69,670,328...69,810,327
|
|
G |
Zfp658 |
zinc finger protein 658 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF782 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:93,992,467...94,005,689
Ensembl chr 1:93,992,469...94,005,687
|
|
G |
Zfp873 |
zinc finger protein 873 |
increases expression |
ISO |
Rifampin results in increased expression of ZNF441 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:7,926,951...7,959,822
Ensembl chr 7:7,926,957...7,951,803
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
rifamycin SV results in decreased activity of ABCB11 protein |
CTD |
PMID:11343252 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Crp |
C-reactive protein |
affects expression |
ISO |
rifamycin SV affects the expression of CRP protein |
CTD |
PMID:1568518 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
rifamycin SV inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite] |
CTD |
PMID:34619012 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions decreases activity |
ISO |
rifamycin SV inhibits the reaction [SLCO1B3 protein results in increased import of 8-sulfocholecystokinin octapeptide]; rifamycin SV inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite] rifamycin SV inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite] rifamycin SV results in decreased activity of SLCO1B3 protein |
CTD |
PMID:27450509 PMID:31364238 PMID:34619012 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Aadac |
arylacetamide deacetylase |
multiple interactions decreases acetylation |
ISO |
AADAC mRNA affects the reaction [rifapentine results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of rifapentine] |
CTD |
PMID:21856291 |
|
NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
rifapentine results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
rifapentine binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
AADAC mRNA affects the reaction [rifapentine results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:16837568 PMID:21856291 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
rifapentine binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ABCB1A mRNA rifaximin results in increased expression of ABCB1 mRNA |
CTD |
PMID:21141967 PMID:22790967 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of ACTA2 mRNA |
CTD |
PMID:22790967 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of APOA4 mRNA |
CTD |
PMID:22790967 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein] |
CTD |
PMID:21599020 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein |
CTD |
PMID:22790967 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mRNA |
CTD |
PMID:22790967 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CIDEC mRNA |
CTD |
PMID:22790967 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of COL1A1 mRNA |
CTD |
PMID:22790967 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Rifaximin results in increased expression of CYP3A4 mRNA [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA |
CTD |
PMID:21141967 PMID:22790967 PMID:27506419 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7A1 protein |
CTD |
PMID:22790967 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CYP7B1 protein |
CTD |
PMID:22790967 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of DGAT2 mRNA |
CTD |
PMID:22790967 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of FABP2 protein |
CTD |
PMID:22790967 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein] |
CTD |
PMID:21599020 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of IL10 protein |
CTD |
PMID:21599020 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Lta |
lymphotoxin alpha |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of LTA mRNA |
CTD |
PMID:22790967 |
|
NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] |
CTD |
PMID:21599020 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of NR1H4 protein |
CTD |
PMID:22790967 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases response to substance increases expression increases activity |
ISO |
4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; 4,4'-hexafluorisopropylidene diphenol metabolite inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased abundance of Triglycerides; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ABCB1A mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of ACTA2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of APOA4 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CD36 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CFD mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CIDEC mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of COL1A1 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP3A11 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7A1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of CYP7B1 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of DGAT2 mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of FABP2 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of LTA mRNA; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of NR1H4 protein; [NR1I2 results in increased susceptibility to Rifaximin] which results in increased expression of PPARG mRNA; [Rifaximin binds to and results in increased activity of NR1I2 protein] which results in decreased susceptibility to Trinitrobenzenesulfonic Acid; bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate inhibits the reaction [Rifaximin results in increased activity of NR1I2 protein]; Rifaximin binds to and results in increased activity of NR1I2 protein NR1I2 results in increased susceptibility to rifaximin rifaximin results in increased expression of NR1I2 mRNA [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CCL3 protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IFNG protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein]; [Rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] |
CTD |
PMID:21599020 PMID:22291955 PMID:22790967 PMID:27506419 PMID:30408883 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of PPARG mRNA |
CTD |
PMID:22790967 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[rifaximin co-treated with Trinitrobenzenesulfonic Acid] results in increased expression of TGFB1 protein |
CTD |
PMID:21599020 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; rifaximin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein] |
CTD |
PMID:21599020 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|